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Tumor growth is an evolutionary process governed by somatic mutation, clonal 
selection and random genetic drift, constrained by the co-evolution of the 
microenvironment1,2. Tumor subclones are subpopulations of tumor cells with a common set 
of mutations resulting from the expansion of a single cell during tumor development, and 
have been observed in a significant fraction of cancers and across multiple cancer types3. 
Peter Nowell proposed that tumors evolve through sequential genetic events4, whereby one 
cell acquires a selective advantage so that its lineage becomes predominant. According to this 
traditional model, the selective advantage is conferred by a small set of driver mutations, but, 
as the subclones that bear them expand successively, they accumulate passenger mutations as 
well, which can be detected in sequencing experiments1. Genomes of individual tumors 
contain hundreds to many thousands of these genetic variants, at a wide range of 
frequencies5,6. Given that genetic drift alone can drive novel variants to high frequencies, it is 
of great interest to discern the relative importance of selection and drift in shaping the 
frequency distribution of variants in any given tumor.   
Williams et al.7 recently proposed a way to do so. They found that a simple model of 
tumor growth in which all novel variants are selectively neutral, that is, whose dynamics are 
governed entirely by drift, predicts a linear relationship between the number of mutations 𝑀(𝑓) present in a fraction f of cells and the reciprocal of that fraction: 𝑀 𝑓 ∝    !!. They 
argued that deviation from this null model, i.e. the R-squared of the linear fit is below the 
minimum observed in neutral simulations (R2 < 0.98), indicates the presence of selection and 
that this can be tested by means of variant allele frequencies (VAFs) from which f can be 
derived. Applying this rationale to real cancer data from The Cancer Genome Atlas (TCGA), 
the test proposed by Williams et al. did not reject the null model, that is neutrality, in about 
one third of the cases and the authors concluded that these tumors are neutrally evolving. 
More recently, multiple myelomas with evidence for the proposed linear relationship were 
associated with poorer prognosis8.  
While providing an interesting approach to infer selection in human cancers, 
unfortunately four major simplifying assumptions underlie the analysis by Williams et al. that 
might render the conclusions questionable.  
First, inferring f of variants from their VAF requires accurate estimates of local copy 
number, overall tumor purity and ploidy. Williams et al. attempted to account for some of 
these factors by restricting their analyses to variants with VAF between 0.12 and 0.24 and 
located in copy-neutral regions of the genome. However, even in that limited VAF window, 
the VAF of a mutation does not reflect its true f in many cases. For example, in tumors with 
whole genome duplications, i.e. 37% of tumors in the analyzed dataset9, the peak of clonal 
mutations acquired after the whole genome doubling event is at or below VAF = 0.25 (one 
out of four copies in a 100% pure tumor sample), which would lead to artificial deviation 
from the linear fit within that VAF window.  
Second, the interpretation of the analyses is inconsistent with the use of neutrality as 
a null model. Failure to reject the null hypothesis is not the same as proving it true, i.e. that 
all neutral simulations have R2 > 0.98 does not prove that non-neutral simulations would 
never yield R2 > 0.98. One would need to demonstrate that this condition is sufficient to infer 
neutrality but also, no equally suited models of non-neutral tumor growth should yield R2 > 
0.98. 
To assess this, we simulated simple tumor growth in which we explicitly model one 
subclonal expansion with a selective advantage, i.e. increasing its division rate λ and/or the 
mutation rate µ of the subclone (Supplementary Methods). Using the original method 
described by Williams et al., neutrality is rejected only within a narrow range of λ and µ 
values tested that would lead to detectable subclones (true rejection of neutrality in ~11% of 
simulations; Fig. 1a). We conclude that a linear fit with R2 > 0.98 is not sufficient to call 
neutrality and that improper use of this model could result in substantial over-calling of 
neutrality. 
Third, the deterministic model of tumor growth described by Williams et al. relies 
on strong biological assumptions, among which are synchronous cell divisions, constant cell 
death and constant mutation and division rates. Stochastic models of tumor growth are 
biologically more realistic, as they allow for asynchronous divisions and probabilistic 
mutation acquisition, cell death and division rates. Using simple branching processes to 
simulate neutral and non-neutral growth10 (Supplementary Methods), we show that R2 > 
0.98 for 𝑀 𝑓 ∝    !! is neither a necessary nor a sufficient property of neutrally evolving 
tumors (Fig. 1b). Although it can be shown that the expected cumulative number of 
mutations – i.e. the average over many independent samples – 𝑀 𝑓 ∝    !!,10 due to the 
biological noise modeled in branching processes, a typical realization of the neutral process 
in a single sample deviates substantially from the expected linear fit, rendering an R-squared 
threshold inaccurate to infer neutrality. As a result, discrimination of neutral and non-neutral 
simulated tumors using a linear fit is almost arbitrary, with 53.5% false positive neutral calls 
in non-neutral tumors (Fig. 1b) and an area under the ROC curve of 0.42 for the 
classification of 1,919 neutral and 1,919 non-neutral tumors (Fig. 1c). 
Fourth, we reason that in tumors called neutral, no subclonal selection should be 
detected. To evaluate this, we use an orthogonal method to identify selection, based on the 
observed variants themselves rather than on their allele frequencies. dN/dS analysis derives 
the fraction of mutated non-synonymous positions to the fraction of mutated synonymous 
positions in the coding regions. It has been widely used to detect the presence of negative or 
positive selection of non-synonymous variants in coding regions11,12. We applied a dN/dS 
model optimized for the detection of selection in somatic cancer variants13 to TCGA exome 
data  using a published list of 192 cancer genes14 (Supplementary Methods). The analysis 
was performed separately using variants called as clonal or subclonal (Supplementary 
Methods), in tumors called neutral and non-neutral based on the rationale outlined by 
Williams and colleagues7. dN/dS ratio analysis revealed significant positive selection in 
subclonal mutations of tumors classified as neutral (Fig. 1d), further suggesting that the 
approach described by Williams et al. is under-equipped to detect the presence or absence of 
selection. 
In summary, Williams et al. proposed that about one third of tumors are neutrally 
evolving. However, we highlight four simplifying assumptions – to our knowledge not 
previously highlighted – and find that the proposed approach will often identify individual 
tumors as neutral when they are non-neutral and non-neutral when they are neutral. A new 
paper by the same group15 introduces a Bayesian test for detecting selection from VAFs. The 
test estimates selection coefficients and, as such, is an important advance over Williams et 
al.’s frequentist test, which does not. The authors acknowledge that the test can only detect 
large fitness differences, but nevertheless call tumors that fail it “neutral’’ when they are 
merely those in which a weak test has failed to detect selection. We note that neutral theory 
has been developed in population genetics, ecology and cultural evolution and that similar 
tests have been proposed in all of these fields and, in all, eventually been found wanting for 
the same reason: variant abundance distributions do not contain enough information to 
exclude selection16–18. It is of clinical importance to identify and better understand the drivers 
of the potentially more aggressive (sub)clones expanding under selective biological or 
therapeutic pressure, as these are good candidates for predicting resistance and exploring 
combination therapy. Williams et al. are to be commended for having introduced explicit 
.
neutral tumor growth models into tumor genomics. However, quantifying the relative 
importance of drift and selection in shaping the allele frequencies of single tumors clearly 
remains an open challenge. Studies relying on their proposed test (e.g. 8) might, then, need 
reevaluation. 
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Figure 1 legend 
(a) Neutrality calls in simulations of tumor growth with subclonal expansion underlying 
selective sweeps. The tree topology being modelled is represented on the right together with the 
parameters of the neutral evolution equations for the two subpopulations of cells (Supplementary 
Methods). The subclone’s fraction (subclone %) increases with its selective advantage advsubclone. 
We vary the λ = 1 + advsubclone and µ parameters of the subclone along a grid. Simulations are 
defined as true non-neutral (light blue) or false neutral (dark blue) when the growing subclone has 
expanded sufficiently to be detectable and the sweep is not complete, i.e. 10% ≤ subclone % ≤ 
90%, otherwise the subclone is considered beyond detection (light green). Non-neutral call: 
R2 < 0.98; neutral call: R2 ≥ 0.98. (b) As (a), using the Gillespie algorithm to simulate 
branching processes10. Simulations leading to subclones beyond detection are either called neutral 
(light green) or non-neutral (dark green). Because of the stochastic nature of branching processes, 
different subclone % values are obtained across simulations from the same advsubclone values. For 
five increasing advsubclone values, we report median ± mad of the subclone % across the simulations. 
(c) Summary ROC curve for the neutral vs. non-neutral classification based on the R2 values 
in 1,919 non-neutral simulations from (b), and 1,919 simulations of neutral tumors. The false 
positive rate and the true positive rate are highlighted for R2 = 0.98 used by Williams et al. (d) 
dN/dS analysis. Maximum likelihood estimates of the dN/dS ratios and associated 95% confidence 
intervals for (sub)clonal mutations in TCGA tumors categorized into neutral and non-neutral 
groups. Ratios for missense and truncating mutations are given. dN/dS > 1 indicates positive 
selection. 
Members of the PCAWG Evolution and Heterogeneity Working Group 
Stefan C. Dentro1,2,3,*, Ignaty Leshchiner4,*, Moritz Gerstung5,*, Clemency Jolly1,*, Kerstin 
Haase1,*, Maxime Tarabichi1,2,*, Jeff Wintersinger6,7,*, Amit G. Deshwar6,7,*, Kaixian Yu8,*, 
Santiago Gonzalez5,*, Yulia Rubanova6,7,*, Geoff Macintyre9,*, David J. Adams2, Pavana 
Anur10, Rameen Beroukhim4,11, Paul C. Boutros6,12, David D. Bowtell13, Peter J. Campbell2, 
Shaolong Cao8, Elizabeth L. Christie13,14, Marek Cmero14,15, Yupeng Cun16, Kevin J. 
Dawson2, Jonas Demeulemeester1,17, Nilgun Donmez18,19, Ruben M. Drews9, Roland Eils20,21, 
Yu Fan8, Matthew Fittall1, Dale W. Garsed13,14, Gad Getz4,22,23,24, Gavin Ha4, Marcin 
Imielinski25,26, Lara Jerman5,27, Yuan Ji28,29, Kortine Kleinheinz20,21, Juhee Lee30, Henry Lee-
Six2, Dimitri G. Livitz4, Salem Malikic18,19, Florian Markowetz9, Inigo Martincorena2, 
Thomas J. Mitchell2,31, Ville Mustonen32, Layla Oesper33, Martin Peifer16, Myron Peto10, 
Benjamin J. Raphael34, Daniel Rosebrock4, S. Cenk Sahinalp19,35, Adriana Salcedo12, 
Matthias Schlesner20, Steven Schumacher4, Subhajit Sengupta28, Ruian Shi6, Seung Jun 
Shin8,36, Lincoln D. Stein12, Ignacio Vázquez-García2,31, Shankar Vembu6, David A. 
Wheeler37, Tsun-Po Yang16, Xiaotong Yao25,26, Ke Yuan9,38, Hongtu Zhu8, Wenyi Wang8,#, 
Quaid D. Morris6,7,#, Paul T. Spellman10,#, David C. Wedge3,39,#, Peter Van Loo1,17,# 
1The Francis Crick Institute, London NW1 1AT, United Kingdom; 2Wellcome Trust Sanger Institute, 
Cambridge CB10 1SA, United Kingdom; 3Big Data Institute, University of Oxford, Oxford OX3 7LF, 
United Kingdom; 4Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; 5European 
Molecular Biology Laboratory, European Bioinformatics Institute, Cambridge CB10 1SD, United 
Kingdom; 6University of Toronto, Toronto, ON M5S 3E1, Canada; 7Vector Institute, Toronto, ON 
M5G 1L7, Canada; 8The University of Texas MD Anderson Cancer Center, Houston, TX 77030, 
USA; 9Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, 
United Kingdom; 10Molecular and Medical Genetics, Oregon Health & Science University, Portland, 
OR 97231, USA; 11Dana-Farber Cancer Institute, Boston, MA 02215, USA; 12Ontario Institute for 
Cancer Research, Toronto, ON M5G 0A3, Canada; 13Peter MacCallum Cancer Centre, Melbourne, 
VIC 3000, Australia; 14University of Melbourne, Melbourne, VIC 3010, Australia; 15Walter + Eliza 
Hall Institute, Melbourne, VIC 3000, Australia; 16University of Cologne, 50931 Cologne, Germany; 
17University of Leuven, B-3000 Leuven, Belgium; 18Simon Fraser University, Burnaby, BC V5A 1S6, 
Canada; 19Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; 20German Cancer Research 
Center (DKFZ), 69120 Heidelberg, Germany; 21Heidelberg University, 69120 Heidelberg, Germany; 
22Massachusetts General Hospital Center for Cancer Research, Charlestown, MA 02129, USA; 
23Massachusetts General Hospital, Department of Pathology, Boston, MA 02114, USA; 24Harvard 
Medical School, Boston, MA 02215, USA; 25Weill Cornell Medicine, New York, NY 10065, USA; 
26New York Genome Center, New York, NY 10013, USA; 27University of Ljubljana, 1000 Ljubljana, 
Slovenia; 28NorthShore University HealthSystem, Evanston, IL 60201, USA; 29The University of 
Chicago, Chicago, IL 60637, USA; 30University of California Santa Cruz, Santa Cruz, CA 95064, 
USA; 31University of Cambridge, Cambridge CB2 0QQ, United Kingdom; 32University of Helsinki, 
00014 Helsinki, Finland; 33Carleton College, Northfield, MN 55057, USA; 34Princeton University, 
Princeton, NJ 08540, USA; 35Indiana University, Bloomington, IN 47405, USA; 36Korea University, 
Seoul, 02481, Republic of Korea; 37Human Genome Sequencing Center, Baylor College of Medicine, 
Houston, TX 77030, USA; 38University of Glasgow, Glasgow G12 8RZ, United Kingdom; 39Oxford 
NIHR Biomedical Research Centre, Oxford OX4 2PG, United Kingdom.  
*: These authors contributed equally 
#: These authors jointly directed the work 
1 
Neutral tumor evolution? - Methods 
Outline 
First, we describe the two tumor growth models that were used. The first is 
based on the deterministic continuous model presented by Williams et al.1. The 
second is based on a branching process, a commonly used discrete and fully 
stochastic growth model. We next explain how, using these two models, we can 
simulate variant allele fractions encountered in tumor sequencing studies. We 
describe our implementation of the approach by Williams et al.1 to infer the most 
likely evolutionary path after the emergence of the most recent common ancestor 
(MRCA), i.e. neutral vs. non-neutral evolution. Finally, using real data from The 
Cancer Genome Atlas, we compare neutrality calls to results of dN/dS analysis, an 
independent and well-established approach to detect selection. We further describe 
the availability of the code as a tarball containing R and Java scripts and a Java 
runnable jar file called via one of the R scripts. 
Simulations – continuous deterministic models 
The deterministic equations described in Williams et al.1 relate the number of 
cells in a tissue growing exponentially, N, 𝑁 𝑡 = 2!"# 
and the cumulative number of mutations, M: 𝑀 𝑡 = 𝜇 2!"!!𝑑𝑡! = !!" !" !!! 2!"# − 1 = !!" !" ! (𝑁 𝑡 − 1)        (Eq. 1) 
at any given time t ≥ 0, where λ > 0 is the division rate per unit of time, β ≥ 0 is the 
unitless “effective” division fraction, i.e. the fraction of divisions in which both 
daughter cells survive (β = 1 for no cell death, β < 1 to model cell death), and µ > 0 is 
the mutation rate per cell division.  
We have used these continuous deterministic models to simulate tumor growth 
in silico and followed each mutation and its corresponding variant cell fraction. To 
derive the cell fractions, we follow the progeny of the mother cell within which each 
mutation occurred.  
2 
Assume that the MRCA appears at time t1, with division coefficient β1, 
division rate λ1, and mutation rate µ1. To model a selective sweep within the cell 
population spawned from the MRCA, we assume that at time t2 > t1, a subclone is 
initiated with division coefficient β2, division rate λ2, and mutation rate µ2.  
There is positive selection when λ2β2 > λ1β1. At time t the number of cells 
spawned from the MRCA but not part of the subclone (i.e. the cells with parameters 
β1, λ1, µ1; further referred to as the MRCA lineage) is  𝑁!(𝑡) = 2!!!!(!!!!) − 2!!!!(!!!!)
where the second term is omitted when t < t2. Similarly, the number of cells at time t 
from the subclonal lineage (i.e. with parameters β2, λ2, µ2) is 𝑁!(𝑡) = 2!!!!(!!!!) 
when t > t2 and N2(t) = 0 otherwise. The total cell count at time t is 𝑁 𝑡 = 𝑁! 𝑡 + 𝑁!(𝑡). 
The tumor growth simulation is terminated at time T > t2 and we derive the 
distribution at time T of the cell fractions for all mutations in the tumor.  
Following the number of mutations and their cell fraction 
Because the equations are continuous, they can lead to non-integer numbers of 
mutations and cell divisions. Hence, rather than deriving the number of mutations and 
their allele frequencies f at discrete time points, we model divisions in continuous 
time. We assess the number of additional mutations that have been added in fixed 
(small) time intervals of length dt. From Eq. (1), we find that the number of additional 
mutations occurring in the time interval [t, t + dt] within a population of cells from the 
same lineage (i.e. parameters β, division rate λ, and mutation rate µ) is: 𝑀 𝑡 + 𝑑𝑡 −𝑀 𝑡 = 𝜇 1𝜆𝛽 ln 2 (𝑁 𝑡 + 𝑑𝑡 − 𝑁(𝑡)) 
For a mutation occurring at time t, we may compute the variant cell fraction at 
time T. If the mutation occurred in a cell from the MRCA lineage that was not 
inherited by the subclone-initiating cell, then the variant cell fraction is 𝑓! 𝑡 = 2!!!!(!!!)𝑁(𝑇)
If the mutation occurred in the subclone, then the variant cell fraction is 
3 
𝑓! 𝑡 = 2!!!!(!!!)𝑁(𝑇)
Finally, if the mutation occurred in an ancestor cell of the subclone-initiating 
cell, then the variant cell fraction is 𝑓!" 𝑡 = 2!!!!(!!!) − 2!!!!(!!!!) + 2!!!!(!!!!)𝑁(𝑇)
Alternatively, we may calculate variant cell fractions in two steps, first 
determining the variant cell fraction of a mutation within the subpopulation of cells 
from the same lineage, and then scaling the variant cell fraction by the size of that 
subpopulation relative to the total cell population.  
Setting the parameters for the grid of simulations 
In each of our simulations the subclone growing under selective advantage 
appears at the 11th generation and the tumor is sampled at the 40th generation with a 
virtual purity of 100%. The number of initial clonal mutations µ0 is not part of these 
models, and we arbitrarily set µ0 = µ2. We fix the following parameters: clonal 
mutation rate µ1 = 16, clonal division rate λ1 = 1, clonal division efficiency β1 = 0.4, 
subclonal β2 = 0.4. The depth of sequencing of the variants cov ~ Pois(10,000) to 
approach the theoretical distribution and the alternate read counts ~ Bin(cov, f/2), 
where f is the variant allele frequency derived from the model (see section on 
simulating tumor variant allele frequencies from sequencing data). We explore the 
results of the neutrality calls for a grid of parameter values wide enough to encompass 
many realistic combinations: 𝜇! = 2!.!! !∈ !,!,…,!" − 0.5
and 𝑎𝑑𝑣!"#$%&'( = (0.01𝑛)!∈ !,!,!,…,!" , 
where 𝑎𝑑𝑣!"#$%&'( = 𝜆! − 𝜆!. 
4 
Simulations – fully stochastic models 
To model stochastic discrete tumor growth, we use branching processes with 
the Gillespie algorithm2. These simulated tumors grow under asynchronous division, 
with zero or one subclone.  
This was coded in Java. Each cell is a Java object and has four attributes: a 
Boolean value reporting whether the cell is alive or dead; an integer for the average 
number of mutations per division; an integer with mother cell ID; and an ArrayList of 
all MutationSets inherited from the mother cell. MutationSet is another class, for 
which each object contains one integer for the mother cell ID and one integer for the 
number of mutations within them. The constructor of MutationSet takes the mutation 
rate of the mother cell as average number of events per interval of a Poisson 
distribution to draw the number of mutations. 
Starting with an ArrayList of one tumor initiating cell, for each of 220 cell 
division events, one cell is picked randomly from the living cells and either dies with 
probability P(cell death) or divides into two daughter cells with probability 
P(division) = 1 - P(cell death), akin to the Gillespie algorithm.  
In our simulations, the subclone appears at the 28 th division (~8th generation) 
by changing the division rate value of one of the cells, and the tumor is sampled at the 
220 th division (~20th generation). In these simulations, the number of mutations 
acquired at each cell division for each daughter cell is drawn from a Poisson 
distribution for the MRCA lineage µ ~ Pois(µMRCA) and the subclone lineage 
µ ~ Pois(µsubclone).  
The subclone is selected for division with probability 𝑃(𝑠𝑢𝑏𝑐𝑙𝑜𝑛𝑒  𝑑𝑖𝑣𝑖𝑑𝑒𝑠) = (1+ 𝑎𝑑𝑣!"#$%&'()𝑁!"#$%&'(1+ 𝑎𝑑𝑣!"#$%&'( 𝑁!"#$%&'( + 𝑁!"#$
where Nsubclone and NMRCA are the number of cells from the subclonal lineage and the 
MRCA lineage, respectively, and advsubclone > 0 for positive selection and 
advsubclone = 0 for neutral growth. The MRCA population will be selected for division 
with probability 1 - P(subclone divides). 
Within the selected clone, one cell is selected randomly for division with 
probability 𝑃 𝑐𝑒𝑙𝑙  𝑑𝑖𝑣𝑖𝑑𝑒𝑠 = 1𝑁
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where N = NMRCA if the cells belong to the MRCA lineage or N = Nsubclone if the cell 
belongs to the subclonal lineage. 
With higher P(cell death), the first divisions are more likely to lead to the 
death of all cells and the tumor quickly stops growing. To limit this effect when cell 
death is high, we force the D first divisions to happen, i.e. P(cell death) = 0 transiently 
until at least 2D cells are alive.  
Setting the parameters for the grid simulations 
In our simulations, starting from one tumor initiating cell, for each of the 220 
cell division events, one cell is picked randomly and either dies with probability 
P(cell death) = 0.2 or divides into two daughter cells with probability P(division) = 1 - 
P(cell death) = 0.8. The subclone appears at the 28 th division (~8th generation) and the 
tumor is sampled at the 220-th division (~20th generation). The ancestor clone’s 
mutation rate µ ~ Pois(16). The average depth of coverage is 100X (see section on 
simulating tumor variant allele frequencies from sequencing data). In our simulations, 
D = 6. 
We explore a grid of values for 𝜇!"#$%&'( = 2!.!! !∈ !,!,…,!" − 0.5
and 𝑎𝑑𝑣!"#$%&'( = (0.01𝑛)!∈ !,!,!,…,!"" . 
This leads to 19*101=1,919 simulated tumor simulations covering the grid. 
Simulating tumor variant allele frequencies from sequencing data 
Using the tumor growth models presented here, we can derive the exact 
number of mutations and their prevalence within a virtual tumor. These are taken as 
input to simulate the frequencies that would be observed in the sequencing reads from 
real tumor tissue. 
In order to test the initial hypothesis, i.e. 𝑀(𝑓) ∝ !! 𝑛𝑒𝑢𝑡𝑟𝑎𝑙𝑖𝑡𝑦, we start 
with the simplest models and assume: (i) the absence of non-tumor contaminant, (ii) 
100% of the tumor cells are resected, and (iii) a fully diploid cancer genome.  
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Given exact cell fractions, f, of each mutation and an average sequencing 
coverage, cov, we draw for each individual mutation the total number of reads 
covering its genomic position N from a Poisson distribution N ~ Pois(cov), and the 
alternate read counts alt ~ Bin(N,f/2), where f/2 is the allelic fraction for diploid 
regions. Finally, we generate variant calls by taking mutations with alt > 2 and derive 
the variant allelic fraction (VAF) of each variant 𝑉𝐴𝐹 =    !"#! . We then use the VAF 
distribution to call neutral and non-neutral tumors, as described by Williams et al.1 
Calling neutral tumors 
We followed the description by Williams et al.1 to call neutral and non-neutral 
tumors based on the variant allele frequencies of their somatic single nucleotide 
variants. Tumors with less than 12 mutations with 0.12 ≤ VAF ≤ 0.24 were removed.  
From the TCGA dataset, only tumors with a purity of at least 70%, as inferred by 
ASCAT3, were analyzed.  
We calculated the explained variance (R2) for linear regression models both 
with fixed intercept (intercept = 0) and without fixing the intercept, using the R 
commands: 
> summary(lm(y~x+0,offset=rep(0,length(y))))$r.squared, 
and  
> cor(x,y)^2  
respectively, where y is the cumulative number of mutations and x is the inverse 
allelic frequency minus the upper limit 𝑥 = !! − !!.!" . Results presented in the 
manuscript were obtained using a variable intercept. In Supplementary Fig. 1, we 
show the heat map of Figure 1a using a fixed intercept. Both methods show 97.5% 
agreement (Supplementary Fig. 2). 
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Supplementary figure 1. As reported in figure 1a using R2 of a linear regression with fixed intercept = 0. The 
tree topology being modelled is represented on the right together with the parameters of the neutral evolution 
equations for the two subpopulations of cells. The subclone’s fraction (subclone %) increases with its selective 
advantage advsubclone. We vary the λ = 1 + advsubclone and µ parameters of the subclone along a grid. Simulations are 
defined as true non-neutral (light blue) or false neutral (dark blue) when the growing subclone is sizable enough to 
be detected and the sweep is not complete, i.e. 10% ≤subclone % ≤ 90%, otherwise the subclone is considered 
beyond detection (light green). Non-neutral call: R2 < 0.98; neutral call: R2 ≥ 0.98. 
Supplementary figure 2. R2 values for the same simulations as in Supplementary figure 2, with variable and 
fixed intercept, showing an agreement of 97.5% on the neutral calls. The x-axis represents R2 values (squared 
Pearson’s correlation coefficients) for the linear regression between M(f) and f for the simulations in Supp. Fig. 1. 
0.
0
0.
2
0.
4
0.
6
0.
8
µsubclone
ad
v s
ub
clo
ne
21 22 23 24 25 26 27 28 29 210
6% subclone
25% subclone
62% subclone
89% subclone
98% subclone
100%
subclone%
µ=16
λ=1
β=0.4
µ=µsubclone
λ=1 + advsubclone
β=0.4
false neutral
beyond detection (non−neutral)
beyond detection (neutral)
true non−neutral
0.86 0.90 0.94 0.98
0.
88
0.
92
0.
96
1.
00
ρPearson
2
R2
 w
ith
 fix
ed
 in
te
rc
ep
t agreement
disagreement
8 
The y-axis represents R2 values with fixed intercept = 0. Neutral calls, made if R2 ≥ 0.98, agree for 97.5% of these 
simulations (grey) and disagree for 2.5% of them (red). 
ROC and area under the curve 
Using fully stochastic branching processes, we simulated 1,919 non-neutral 
tumors and 1,919 neutral tumors and derived the R2 values of the linear fit between 
the cumulative number of mutations and their inverse variant allelic fraction (VAF) 
within 0.12 ≤ VAF ≤ 0.24. We then plotted the ROC using the R package ROCR 
version 1.0-7 and calculated the false positive rate and the true positive rate assuming 
the  R2 = 0.98 threshold used by Williams et al.1 
Detection of selection in neutral and non-neutral tumors - dN/dS 
Dataset 
We ran our analyses on the data from The Cancer Genome Atlas, using 
CaVeMan4,5 single nucleotide variant calls, and ASCAT3 copy number calls, as 
described by Martincorena et al.6  
Grouping variants into clonal and subclonal categories 
To classify variants as clonal or subclonal, we used a one-sided proportion test 
to assess whether the alternate and total read counts of each variant were compatible 
with its clonality, given its underlying number of DNA copies, and the overall tumor 
purity. This method is previously described in Alexandrov et al.7 
dN/dS analysis and control gene sets 
We performed dN/dS analysis to detect positive or negative selection of non-
synonymous variants, as described by Martincorena et al.6 The R package dNdScv 
was used to derive the dN/dS values and is available on github: 
https://github.com/im3sanger/dndscv. We ran dN/dS separately on clonal and 
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subclonal mutations and separately in the neutral and non-neutral tumors, using a 
published list of 192 cancer genes (COSMIC v.80 - cancer.sanger.ac.uk8)a. 
As a control, we ran dN/dS on subclonal mutations using 100 random sets of 
192 genes, uniformly sampled from 20,090 annotated genes from hg196. The 95% 
interval of dN/dS values was above 1, i.e. showed evidence for positive selection, in 3 
out 100 random gene sets. We further reasoned that not all genes are equally 
“important” to the 192 COSMIC genes across tissues and took their gene expression 
across tissues as a proxy for their importance. We downloaded the human bodymap 
2.0 (https://www.ebi.ac.uk/gxa/experiments/E-MTAB-513/Results) TPM matrix of 
expression and ranked genes by their values. We summed the ranks across relevant 
tissues (adrenal gland, brain, breast, colon, kidney, leukocyte, liver, lung, ovary, 
prostate gland, thyroid gland) and rerun dN/dS on 4x100 192-gene sets randomly 
sampled from the 10,000, 5,000, 2,500 and 1,000 top-ranked (highly-expressed) genes 
in those tissues. Among these four lists of highly expressed genes, the 95% intervals 
of dN/dS values were >1 in 2, 6, 4, 5 out of the 4x100 gene sets, respectively, 
confirming that the dN/dS signal is (cancer-)gene specific and is not biased in random 
gene sets. We then reasoned that gene co-expression levels might be a better proxy for 
“cancer-relevance” of the genes. To this end, the tool Gemma9 
(https://gemma.msl.ubc.ca/home.html) was run to identify genes showing evidence 
for co-expression with one of the 192 cancer genes in >21 out of 442 gene expression 
datasets from the Master set for human. This identified 2,089 unique co-expressed 
genes (with a median of 2 co-expressed genes per cancer gene), from which we 
removed the 227 genes overlapping with the 719 cancer genes from the most recent 
cancer gene census (COSMIC v.84 - cancer.sanger.ac.uk8). We then sampled 192 
unique genes from the 1,862 genes with probabilities of each gene g being sampled 𝑃 𝑔𝑒𝑛𝑒  𝑔  𝑖𝑠  𝑠𝑎𝑚𝑝𝑙𝑒𝑑 = !!!!∈! , where G are the genes from the 192 genes that are
a
ABL1, ACVR1, ACVR1B, AKT1, ALK, AMER1, APC, AR, ARID1A, ARID2, ASXL1, ATM, ATP1A1, ATP2B3, ATR, ATRX, 
AXIN1, AXIN2, BAP1, BCOR, BIRC3, BRAF, BRCA1, BRCA2, CACNA1D, CALR, CARD11, CASP8, CBL, CBLB, CD79A, 
CD79B, CDC73, CDH1, CDKN2A, CDKN2C, CEBPA, CIC, CNOT3, COL2A1, CREBBP, CRLF2, CSF1R, CSF3R, CTNNA1, 
CTNNB1, CUX1, CXCR4, CYLD, DAXX, DICER1, DNM2, DNMT3A, EGFR, EML4, EP300, ERBB2, ERG, ESR1, ETNK1, 
EZH2, FAT1, FAT4, FBXO11, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, FOXA1, FOXL2, FUBP1, GATA1, GATA2, GATA3, 
GNA11, GNAQ, GNAS, GRIN2A, H3F3A, H3F3B, HIF1A, HIST1H3B, HNF1A, HRAS, IDH1, IDH2, IKBKB, IKZF1, IL6ST, 
IL7R, JAK1, JAK2, JAK3, KCNJ5, KDM5C, KDM6A, KDR, KIT, KLF4, KMT2C, KMT2D, KRAS, MAP2K1, MAP2K2, 
MAP2K4, MAX, MED12, MEN1, MET, MLH1, MPL, MSH2, MSH6, MTOR, MYD88, MYOD1, NF1, NF2, NFE2L2, NFKBIE, 
NOTCH1, NOTCH2, NPM1, NRAS, NT5C2, NTRK3, PAX5, PBRM1, PDGFRA, PHF6, PHOX2B, PIK3CA, PIK3R1, PLCG1, 
POLE, POT1, PPP2R1A, PPP6C, PRDM1, PRKACA, PRKAR1A, PTCH1, PTEN, PTPN11, PTPN13, PTPRB, RAC1, RAD21, 
RB1, RET, RHOA, RNF43, RPL10, RPL5, RUNX1, SETBP1, SETD2, SF3B1, SH2B3, SMAD4, SMARCA4, SMARCB1, SMO, 
SOCS1, SPEN, SPOP, SRC, SRSF2, STAG2, STAT3, STAT5B, STK11, SUFU, TBL1XR1, TBX3, TERT, TET2, TNFAIP3, 
TNFRSF14, TP53, TRAF7, TSC1, TSC2, TSHR, U2AF1, UBR5, USP8, VHL, WT1, XPO1, ZRSR2.
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co-expressed with g, and Ni is the number of co-expressed genes with gene i. We ran 
dN/dS again on 100 of these 192-gene sets and found that 4 and 5 out of 100 gene 
lists yielded 95% confidence intervals of dN/dS >1 for subclonal mutations in neutral 
and non-neutral tumours, respectively. 
Effect of copy number 
We repeated the analyses after selecting only variants that fall within diploid 
regions, i.e. 1 copy of allele A and 1 copy of allele B according to ASCAT3, to show 
that the results were not induced by unreliable neutral calls, which could have resulted 
from the distortion of allele frequencies by copy number changes (Supplementary 
Fig. 3). 
Supplementary Figure 3. dN/dS ratios on all mutations vs. mutations in diploid regions only. Maximum 
likelihood estimates of the dN/dS ratios and associated 95% confidence intervals for (sub)clonal mutations in 
TCGA tumors categorized into neutral and non-neutral groups. Ratios for missense and truncating mutations are 
given. dN/dS > 1 indicates positive selection. 
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Code reproducibility and availability 
Analyses and figures were generated using R version 3.1.3. The branching 
processes are coded in Java. The code for simulations is available as a tarball 
(included within this submission) with R scripts for the deterministic simulations and 
for deriving the figures, and a Java runnable jar file for generating variant fractions 
from the branching processes together with the associated Java source code. 
12 
References 
1. Williams, M. J., Werner, B., Barnes, C. P., Graham, T. A. & Sottoriva, A.
Identification of neutral tumor evolution across cancer types. Nat. Genet. 48, 238–
244 (2016).
2. Bozic, I., Gerold, J. M. & Nowak, M. A. Quantifying Clonal and Subclonal
Passenger Mutations in Cancer Evolution. PLOS Comput. Biol. 12, e1004731
(2016).
3. Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl.
Acad. Sci. 107, 16910–16915 (2010).
4. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF
complex gene PBRM1 in renal carcinoma. Nature 469, 539–542 (2011).
5. Jones et al. cgpCaVEManWrapper: Simple Execution of CaVEMan in Order to
Detect Somatic Single Nucleotide Variants in NGS Data. Curr. Protoc.
Bioinforma. 56, 15.10.1-15.10.18 (2016).
6. Martincorena, I. et al. Universal Patterns of Selection in Cancer and Somatic
Tissues. Cell 171, 1029-1041.e21 (2017).
7. Alexandrov, L. B. et al. Mutational signatures associated with tobacco smoking in
human cancer. Science 354, 618–622 (2016).
8. Forbes, S. A. et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic
Acids Res. 45, D777–D783 (2017).
9. Zoubarev, A. et al. Gemma: a resource for the reuse, sharing and meta-analysis of
expression profiling data. Bioinformatics 28, 2272–2273 (2012).
